A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
Saved in:
| Title: | A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. |
|---|---|
| Authors: | McDermott DH; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Velez D; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Cho E; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Cowen EW; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases., DiGiovanna JJ; Laboratory of Cancer Biology and Genetics and., Pastrana DV; Laboratory of Cellular Oncology, National Cancer Institute., Buck CB; Laboratory of Cellular Oncology, National Cancer Institute., Calvo KR; Department of Laboratory Medicine, Clinical Center., Gardner PJ; Office of the Clinical Director, National Institute of Dental and Craniofacial Research., Rosenzweig SD; Department of Laboratory Medicine, Clinical Center., Stratton P; National Institute of Neurologic Disorders and Stroke., Merideth MA; Office of the Clinical Director, National Human Genome Research Institute., Kim HJ; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and., Brewer C; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and., Katz JD; Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA., Kuhns DB; Leidos Biomedical Research Inc., Frederick, Maryland, USA., Malech HL; Laboratory of Clinical Immunology and Microbiology and., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA., Fay MP; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA., Murphy PM; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2023 Oct 02; Vol. 133 (19). Date of Electronic Publication: 2023 Oct 02. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37561579 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22McDermott+DH%22">McDermott DH</searchLink>; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases.<br /><searchLink fieldCode="AU" term="%22Velez+D%22">Velez D</searchLink>; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases.<br /><searchLink fieldCode="AU" term="%22Cho+E%22">Cho E</searchLink>; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases.<br /><searchLink fieldCode="AU" term="%22Cowen+EW%22">Cowen EW</searchLink>; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases.<br /><searchLink fieldCode="AU" term="%22DiGiovanna+JJ%22">DiGiovanna JJ</searchLink>; Laboratory of Cancer Biology and Genetics and.<br /><searchLink fieldCode="AU" term="%22Pastrana+DV%22">Pastrana DV</searchLink>; Laboratory of Cellular Oncology, National Cancer Institute.<br /><searchLink fieldCode="AU" term="%22Buck+CB%22">Buck CB</searchLink>; Laboratory of Cellular Oncology, National Cancer Institute.<br /><searchLink fieldCode="AU" term="%22Calvo+KR%22">Calvo KR</searchLink>; Department of Laboratory Medicine, Clinical Center.<br /><searchLink fieldCode="AU" term="%22Gardner+PJ%22">Gardner PJ</searchLink>; Office of the Clinical Director, National Institute of Dental and Craniofacial Research.<br /><searchLink fieldCode="AU" term="%22Rosenzweig+SD%22">Rosenzweig SD</searchLink>; Department of Laboratory Medicine, Clinical Center.<br /><searchLink fieldCode="AU" term="%22Stratton+P%22">Stratton P</searchLink>; National Institute of Neurologic Disorders and Stroke.<br /><searchLink fieldCode="AU" term="%22Merideth+MA%22">Merideth MA</searchLink>; Office of the Clinical Director, National Human Genome Research Institute.<br /><searchLink fieldCode="AU" term="%22Kim+HJ%22">Kim HJ</searchLink>; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and.<br /><searchLink fieldCode="AU" term="%22Brewer+C%22">Brewer C</searchLink>; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and.<br /><searchLink fieldCode="AU" term="%22Katz+JD%22">Katz JD</searchLink>; Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kuhns+DB%22">Kuhns DB</searchLink>; Leidos Biomedical Research Inc., Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Malech+HL%22">Malech HL</searchLink>; Laboratory of Clinical Immunology and Microbiology and.<br /><searchLink fieldCode="AU" term="%22Follmann+D%22">Follmann D</searchLink>; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Fay+MP%22">Fay MP</searchLink>; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+PM%22">Murphy PM</searchLink>; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227802877%22">The Journal of clinical investigation</searchLink> [J Clin Invest] 2023 Oct 02; Vol. 133 (19). <i>Date of Electronic Publication: </i>2023 Oct 02. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7802877 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1558-8238 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200219738%22">00219738 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Invest <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37561579 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1172/JCI164918 Languages: – Code: eng Text: English Titles: – TitleFull: A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: McDermott DH – PersonEntity: Name: NameFull: Velez D – PersonEntity: Name: NameFull: Cho E – PersonEntity: Name: NameFull: Cowen EW – PersonEntity: Name: NameFull: DiGiovanna JJ – PersonEntity: Name: NameFull: Pastrana DV – PersonEntity: Name: NameFull: Buck CB – PersonEntity: Name: NameFull: Calvo KR – PersonEntity: Name: NameFull: Gardner PJ – PersonEntity: Name: NameFull: Rosenzweig SD – PersonEntity: Name: NameFull: Stratton P – PersonEntity: Name: NameFull: Merideth MA – PersonEntity: Name: NameFull: Kim HJ – PersonEntity: Name: NameFull: Brewer C – PersonEntity: Name: NameFull: Katz JD – PersonEntity: Name: NameFull: Kuhns DB – PersonEntity: Name: NameFull: Malech HL – PersonEntity: Name: NameFull: Follmann D – PersonEntity: Name: NameFull: Fay MP – PersonEntity: Name: NameFull: Murphy PM IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2023 Oct 02 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1558-8238 Numbering: – Type: volume Value: 133 – Type: issue Value: 19 Titles: – TitleFull: The Journal of clinical investigation Type: main |
| ResultId | 1 |